AMAG Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMAG)

$19.05 -0.25 (-1.30 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$19.05
Today's Range$18.80 - $19.70
52-Week Range$11.93 - $25.20
Volume1.85 million shs
Average Volume1.40 million shs
Market Capitalization$681.95 million
P/E Ratio-3.13
Dividend YieldN/A
Beta0.79

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:AMAG
CUSIP00163U10
Phone+1-617-4983300

Debt

Debt-to-Equity Ratio0.94%
Current Ratio1.59%
Quick Ratio1.48%

Price-To-Earnings

Trailing P/E Ratio-3.13320723684211
Forward P/E Ratio-3.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$532.09 million
Price / Sales1.27
Cash Flow$3.18 per share
Price / Cash6.00
Book Value$27.31 per share
Price / Book0.70

Profitability

Trailing EPS($6.08)
Net Income$-2,480,000.00
Net Margins-35.35%
Return on Equity-0.64%
Return on Assets-0.25%

Miscellaneous

Employees545
Outstanding Shares35,370,000

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its quarterly earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company had revenue of $127.40 million for the quarter, compared to the consensus estimate of $128.52 million. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. The firm's revenue was up 46.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.12 EPS. View AMAG Pharmaceuticals' Earnings History.

When will AMAG Pharmaceuticals make its next earnings announcement?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for AMAG Pharmaceuticals.

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2018?

11 analysts have issued 1 year price targets for AMAG Pharmaceuticals' shares. Their forecasts range from $15.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $22.11 in the next twelve months. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Makena auto-injector is approved. AMAG announced today that the Makena auto-injector was approved. Although the PK data revealed a deficiency in the C max and AMAG disclosed that the FDA commented it would likely create a review issue, we suspect most investors believed the approval would occur." (2/14/2018)
  • 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:

  • Gino Santini, Independent Chairman of the Board (Age 60)
  • William K. Heiden, President, Chief Executive Officer, Director (Age 57)
  • Edward Myles CPA, Chief Financial Officer, Senior Vice President - Finance, Treasurer (Age 45)
  • Nathan McBride, Senior Vice President - Innovation Architects, Chief Information Officer
  • Joseph D. Vittiglio, Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary (Age 45)
  • Tony Casciano, Senior Vice President of Sales and Marketing - Hematology and Oncology business
  • Paul Williams, Senior Vice President - Sales and Marketing, Women’s Health
  • Elizabeth Bolgiano, Senior Vice President of Human Resources
  • Julie Krop M.D., Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs (Age 51)
  • Scott T. McMillan Ph.D., Senior Vice President - Quality and Technical Operations

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LLC (9.88%), LSV Asset Management (3.17%), Renaissance Technologies LLC (2.41%), Robeco Institutional Asset Management B.V. (2.20%), Millennium Management LLC (1.82%) and Acadian Asset Management LLC (1.41%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio and Julie Krop. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Acadian Asset Management LLC, LSV Asset Management, Gotham Asset Management LLC, Alambic Investment Management L.P., Guggenheim Capital LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and TIAA CREF Investment Management LLC. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and Julie Krop. View Insider Buying and Selling for AMAG Pharmaceuticals.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Spark Investment Management LLC, Amundi Pioneer Asset Management Inc., Palo Alto Investors LLC, Arizona State Retirement System and Fox Run Management L.L.C.. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $19.05.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $681.95 million and generates $532.09 million in revenue each year. The specialty pharmaceutical company earns $-2,480,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. AMAG Pharmaceuticals employs 545 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 Winter St, WALTHAM, MA 02451-1427, United States. The specialty pharmaceutical company can be reached via phone at +1-617-4983300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AMAG Pharmaceuticals (NASDAQ:AMAG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.272.252.142.08
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.11$21.00$24.27$28.70
Price Target Upside: 59.07% upside58.49% upside73.13% upside64.00% upside

AMAG Pharmaceuticals (NASDAQ:AMAG) Consensus Price Target History

Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018Piper Jaffray CompaniesReiterated RatingHold -> NeutralMediumView Rating Details
2/15/2018Janney Montgomery ScottUpgradeNeutral -> Buy$16.65 -> $45.00HighView Rating Details
2/14/2018Cantor FitzgeraldReiterated RatingHold$17.00HighView Rating Details
2/2/2018Leerink SwannReiterated RatingMarket PerformHighView Rating Details
1/29/2018B. RileyReiterated RatingHold$16.00LowView Rating Details
11/5/2017Jefferies GroupReiterated RatingBuy$16.00N/AView Rating Details
11/3/2017Morgan StanleyLower Price TargetOverweight$26.00 -> $22.00N/AView Rating Details
8/31/2017Deutsche BankReiterated RatingHold$24.00LowView Rating Details
8/10/2017CowenReiterated RatingHoldHighView Rating Details
7/7/2017CitigroupLower Price TargetHold$24.00LowView Rating Details
6/1/2017BarclaysReiterated RatingEqual Weight$25.00 -> $20.00LowView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017JPMorgan Chase & Co.Set Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Raymond James FinancialReiterated RatingMarket Perform -> UnderperformN/AView Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00N/AView Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings History and Estimates Chart

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ AMAG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018$0.04N/AView Earnings Details
11/2/2017Q3 2017($0.04)$1.57$166.83 million$153.74 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.58)($0.40)$158.83 million$158.39 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
2/9/2015Q4 2014$0.30$0.04$53.94 million$53.25 millionViewN/AView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
7/26/2011Q2 2011($1.08)($0.92)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.09)($0.81)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.97)($1.02)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.84)($1.15)ViewN/AView Earnings Details
3/1/2010Q4 2009($1.08)($1.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($1.45)($1.29)ViewN/AView Earnings Details
7/29/2009Q2 2009($1.53)($1.55)ViewN/AView Earnings Details
4/30/2009Q1 2009($1.30)($1.55)ViewN/AView Earnings Details
2/27/2009Q4 2008($1.40)($1.28)ViewN/AView Earnings Details
11/3/2008Q3 2008($1.12)($1.39)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.62)($1.00)ViewN/AView Earnings Details
4/25/2008Q1 2008($0.60)($0.55)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.53)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings Estimates

2018 EPS Consensus Estimate: ($6.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.80)($0.80)($0.80)
Q2 20181($0.68)($0.68)($0.68)
Q3 20181($2.13)($2.13)($2.13)
Q4 20181($2.40)($2.40)($2.40)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2017Joseph VittiglioSVPSell1,250$16.75$20,937.5033,504View SEC Filing  
7/13/2017Julie KropSVPSell4,938$20.00$98,760.0028,336View SEC Filing  
5/1/2017Julie KropSVPSell1,891$24.45$46,234.9536,777View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.4023,668View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.006,086View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00200,721View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00202,721View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.0024,834View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.0028,834View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AMAG Pharmaceuticals (NASDAQ AMAG) News Headlines

Source:
DateHeadline
AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Rating of "Hold" by BrokeragesAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 21 at 2:30 PM
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - GlobeNewswire (press release)AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - GlobeNewswire (press release)
globenewswire.com - February 21 at 8:15 AM
AMAG Pharmaceuticals (AMAG) Scheduled to Post Quarterly Earnings on WednesdayAMAG Pharmaceuticals (AMAG) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ETAMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET
finance.yahoo.com - February 20 at 5:51 PM
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - NasdaqAMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - Nasdaq
www.nasdaq.com - February 20 at 8:12 AM
Blog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk WomenBlog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk Women
finance.yahoo.com - February 20 at 8:12 AM
AMAG Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.44) Per Share (AMAG)AMAG Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.44) Per Share (AMAG)
www.americanbankingnews.com - February 19 at 9:34 AM
AMAG Pharmaceuticals (AMAG) Upgraded to "Hold" by BidaskClubAMAG Pharmaceuticals (AMAG) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - February 18 at 3:32 PM
AMAG Pharmaceuticals, Inc. (AMAG) to Post FY2019 Earnings of ($2.19) Per Share, Cantor Fitzgerald ForecastsAMAG Pharmaceuticals, Inc. (AMAG) to Post FY2019 Earnings of ($2.19) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - February 16 at 3:34 PM
Why AMAG Pharmaceuticals Is Soaring - 24/7 Wall St.Why AMAG Pharmaceuticals Is Soaring - 24/7 Wall St.
247wallst.com - February 16 at 8:13 AM
Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector - MarketWatchAntares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector - MarketWatch
www.marketwatch.com - February 16 at 8:13 AM
Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today - Investorplace.comWhy AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today - Investorplace.com
investorplace.com - February 16 at 8:13 AM
Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today - Motley FoolWhy AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today - Motley Fool
www.fool.com - February 16 at 8:13 AM
AMAG Pharmaceuticals Sees Unusually Large Options Volume (AMAG)AMAG Pharmaceuticals Sees Unusually Large Options Volume (AMAG)
www.americanbankingnews.com - February 16 at 6:38 AM
This Biotech Stock Pops 30% On FDA Nod — 'Slamming Door' On WoesThis Biotech Stock Pops 30% On FDA Nod — 'Slamming Door' On Woes
finance.yahoo.com - February 15 at 5:24 PM
Cowen Drops Coverage on AMAG Pharmaceuticals (AMAG)Cowen Drops Coverage on AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - February 15 at 5:06 PM
AMAG Pharmaceuticals (AMAG) Neutral Rating Reiterated at Piper Jaffray CompaniesAMAG Pharmaceuticals' (AMAG) Neutral Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - February 15 at 4:30 PM
Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing TodayWhy AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today
investorplace.com - February 15 at 1:48 PM
AMAG Pharmaceuticals (AMAG) Upgraded to "Buy" by Janney Montgomery ScottAMAG Pharmaceuticals (AMAG) Upgraded to "Buy" by Janney Montgomery Scott
www.americanbankingnews.com - February 15 at 1:06 PM
AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk WomenAMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
finance.yahoo.com - February 15 at 9:16 AM
Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injectorAntares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector
finance.yahoo.com - February 15 at 9:16 AM
Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto InjectorAntares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector
finance.yahoo.com - February 15 at 9:16 AM
AMAG Pharmaceuticals (AMAG) "Hold" Rating Reaffirmed at Cantor FitzgeraldAMAG Pharmaceuticals' (AMAG) "Hold" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - February 15 at 12:18 AM
Traders Purchase Large Volume of AMAG Pharmaceuticals Call Options (AMAG)Traders Purchase Large Volume of AMAG Pharmaceuticals Call Options (AMAG)
www.americanbankingnews.com - February 14 at 6:34 PM
AMAG Pharmaceuticals (AMAG) vs. Veru (VERU) Financial AnalysisAMAG Pharmaceuticals (AMAG) vs. Veru (VERU) Financial Analysis
www.americanbankingnews.com - February 14 at 5:18 PM
The Week Ahead: Earnings, FDA Actions, And Industry Conferences To WatchThe Week Ahead: Earnings, FDA Actions, And Industry Conferences To Watch
finance.yahoo.com - February 13 at 9:03 AM
Brokers Issue Forecasts for AMAG Pharmaceuticals, Inc.s Q1 2018 Earnings (AMAG)Brokers Issue Forecasts for AMAG Pharmaceuticals, Inc.'s Q1 2018 Earnings (AMAG)
www.americanbankingnews.com - February 8 at 9:52 AM
FDA OKs expanded use for AMAG Pharmas Faraheme; shares up 6% premarket - Seeking AlphaFDA OKs expanded use for AMAG Pharma's Faraheme; shares up 6% premarket - Seeking Alpha
seekingalpha.com - February 5 at 3:37 PM
Health-care ETF tumbles, pressured by pharmaceutical company weakness - MarketWatchHealth-care ETF tumbles, pressured by pharmaceutical company weakness - MarketWatch
www.marketwatch.com - February 5 at 3:37 PM
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme ... - NasdaqAMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme ... - Nasdaq
www.nasdaq.com - February 5 at 3:37 PM
AMAG Pharma (AMAG) Reports FDA Approval of Supplemental New Drug Application for Feraheme (ferumoxytol injection)AMAG Pharma (AMAG) Reports FDA Approval of Supplemental New Drug Application for Feraheme (ferumoxytol injection)
www.streetinsider.com - February 5 at 8:58 AM
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)
finance.yahoo.com - February 5 at 8:58 AM
AMAG Pharmaceuticals (AMAG) Market Perform Rating Reiterated at Leerink SwannAMAG Pharmaceuticals' (AMAG) Market Perform Rating Reiterated at Leerink Swann
www.americanbankingnews.com - February 3 at 6:54 AM
FDA Watchlist: Catalysts To Look Out For This FebruaryFDA Watchlist: Catalysts To Look Out For This February
www.benzinga.com - February 2 at 3:43 PM
Attention Biotech Investors: February PDUFA Catalysts Come CallingAttention Biotech Investors: February PDUFA Catalysts Come Calling
www.benzinga.com - February 1 at 9:09 AM
Traders Buy Large Volume of Put Options on AMAG Pharmaceuticals (AMAG)Traders Buy Large Volume of Put Options on AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - February 1 at 2:08 AM
Double Blessing Or Double Whammy - What Awaits AMAG?Double Blessing Or Double Whammy - What Awaits AMAG?
www.nasdaq.com - January 31 at 3:39 PM
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this FebruaryVertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
finance.yahoo.com - January 31 at 9:03 AM
AMAG Pharmaceuticals (AMAG) Receives Hold Rating from B. RileyAMAG Pharmaceuticals (AMAG) Receives Hold Rating from B. Riley
www.americanbankingnews.com - January 29 at 3:22 PM
AMAG Pharmaceuticals, Inc. (AMAG) Receives Average Rating of "Hold" from AnalystsAMAG Pharmaceuticals, Inc. (AMAG) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 2:12 PM
Commit To Purchase AMAG Pharmaceuticals At $12, Earn 43.9% Annualized Using OptionsCommit To Purchase AMAG Pharmaceuticals At $12, Earn 43.9% Annualized Using Options
www.nasdaq.com - January 23 at 5:30 PM
Zacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.16 Per ShareZacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.16 Per Share
www.americanbankingnews.com - January 20 at 5:16 PM
AMAG Pharmaceuticals (AMAG) Stock Rating Reaffirmed by Piper Jaffray CompaniesAMAG Pharmaceuticals (AMAG) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - January 19 at 12:58 AM
Equities Analysts Offer Predictions for AMAG Pharmaceuticals, Inc.s FY2022 Earnings (AMAG)Equities Analysts Offer Predictions for AMAG Pharmaceuticals, Inc.'s FY2022 Earnings (AMAG)
www.americanbankingnews.com - January 18 at 11:58 PM
AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance - GlobeNewswire (press release)AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance - GlobeNewswire (press release)
globenewswire.com - January 8 at 3:39 PM
AMAG Pharmaceuticals - Uncertainty Remains High Amidst Makena Expiration - Seeking AlphaAMAG Pharmaceuticals - Uncertainty Remains High Amidst Makena Expiration - Seeking Alpha
seekingalpha.com - January 8 at 3:39 PM
An Intrinsic Value Calculation For AMAG Pharmaceuticals Inc (NASDAQ:AMAG) Shows It’s 34.52% UndervaluedAn Intrinsic Value Calculation For AMAG Pharmaceuticals Inc (NASDAQ:AMAG) Shows It’s 34.52% Undervalued
finance.yahoo.com - January 5 at 3:36 PM
Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.10 Per ShareZacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of $0.10 Per Share
www.americanbankingnews.com - January 3 at 9:44 PM
AMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of "Hold" from BrokeragesAMAG Pharmaceuticals, Inc. (AMAG) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 1:42 PM
What Should We Expect From AMAG Pharmaceuticals Inc’s (NASDAQ:AMAG) Earnings Over The Next Few Years?What Should We Expect From AMAG Pharmaceuticals Inc’s (NASDAQ:AMAG) Earnings Over The Next Few Years?
finance.yahoo.com - December 28 at 3:08 PM

SEC Filings

AMAG Pharmaceuticals (NASDAQ:AMAG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AMAG Pharmaceuticals (NASDAQ:AMAG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AMAG Pharmaceuticals (NASDAQ AMAG) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.